Proposed mechanisms include autonomic nervous system modulation and potential direct cardiac effects via GLP-1 receptors
The tradeoff is regulatory: compounded drugs are not FDA-approved 1 and should be discussed carefully with a provider
Reducing macrophages to improve bone marrow stromal cell survival in the contused spinal cord
Importantly, initiation of GLP-1RA may decrease levothyroxine dose requirements in patients with hypothyroidism through weight loss, enhance levothyroxine absorption due to delayed gastrointestinal (GI) transit, and have direct effects on the hypothalamic-pituitary-thyroid axis [23,24,25,26,27,28,29], potentially increasing the risk of thyroid hormone over-replacement (i.e., iatrogenic hyperthyroidism)
None of this is the enemy of GLP-1 treatment
If weight loss as stalled - despite diet, exercise, or medications - the problem is usually metabolic signaling, not effort